跳至主要内容
临床试验/ACTRN12609000173291
ACTRN12609000173291招募中2 期

A Phase II Study of the Impact of Two Different Schedules of Thymoglobulin on the Incidence of Extensive Chronic Graft Versus Host Disease (GVHD) in Undergoing Unrelated Donor or Mismatched Related Donor Stem Cell Transplantation for Haematological Malignancy

The Royal Melbourne Hospital0 个研究点目标入组 120 人开始时间: 2009年4月15日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • 1.age > 18 years
  • 2.undergoing an unrelated or mismatched related peripheral blood stem cell (PBSC) allograft
  • 3.no contra-indication to receiving Thymoglobulin
  • 4.life expectancy >3 months
  • 5.absence of active invasive fungal infection at the time of transplant
  • 6.myeloablative conditioning (including cy/TBI, VP16/TBI fludarabine-melphalan >120mg/m2, fludarabine-busulphan at a dose at least equivalent to 3.2mg/kg intravenous (IV) per day for 4 days and by-cy. IV busulphan will be used, given as a single daily dose of 3.2mg/kg at a rate of 80mg/hr. Monitoring, if available, will be done to conform with local guidelines

排除标准

  • 1.active invasive fungal infection at the time of transplant
  • 2.contra-indication to receiving Thymoglobulin
  • 3.Pregnancy

研究者

相似试验